In yesterday’s Wall Street session, Novavax, Inc. (NASDAQ:NVAX) shares traded at $14.79, up 13.68% from the previous session.
NVAX stock price is now 167.70% away from the 50-day moving average and 148.36% away from the 200-day moving average. The market capitalization of the company currently stands at $2.08B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On May 10, 2024, BofA Securities Upgraded its previous ‘Underperform’ rating to ‘Neutral’ on the stock increasing its target price from $4 to quote $12, while ‘B. Riley Securities’ rates the stock as ‘Buy’
In other news, Dubovsky Filip, President, R&D sold 47,312 shares of the company’s stock on May 14 ’24. The stock was sold for $657,637 at an average price of $13.90. Upon completion of the transaction, the President, R&D now directly owns 38,953 shares in the company, valued at $0.58 million. A total of 4.98% of the company’s stock is owned by insiders.
During the past 12 months, Novavax, Inc. has had a low of $3.53 and a high of $15.00. The fifty day moving average price for NVAX is $5.7116 and a two-hundred day moving average price translates $5.98785 for the stock.
The latest earnings results from Novavax, Inc. (NASDAQ: NVAX) was released for 2024-03-31. The company reported revenue of $93.86 million for the quarter, compared to $80.95 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 15.94 percent.
Novavax, Inc.(NVAX) Company Profile
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
